ES2188759T3 - Derivados de la dolastatina, su preparacion y su uso. - Google Patents

Derivados de la dolastatina, su preparacion y su uso.

Info

Publication number
ES2188759T3
ES2188759T3 ES96918661T ES96918661T ES2188759T3 ES 2188759 T3 ES2188759 T3 ES 2188759T3 ES 96918661 T ES96918661 T ES 96918661T ES 96918661 T ES96918661 T ES 96918661T ES 2188759 T3 ES2188759 T3 ES 2188759T3
Authority
ES
Spain
Prior art keywords
preparation
derivatives
dolastatine
new
antineoplasic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96918661T
Other languages
English (en)
Inventor
Andreas Haupt
Franz Emling
Cynthia A Romerdahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Application granted granted Critical
Publication of ES2188759T3 publication Critical patent/ES2188759T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE DESCRIBEN NUEVOS DERIVADOS DE DOLASTATINA DE FORMULA (I): R 1 R 2 N - CHX - CO - A - B - D - E - (F) T K, EN DONDE R 1 , R 2 , A, B, D, E, F, K, X Y T TIENEN LOS SIGNIFICADOS QUE SE INDICAN EN LA DESCRIPCION, Y LA PREPARACION DE LOS MISMOS. LAS NUEVAS SUSTANCIAS TIENEN EFECTO ANTINEOPLASICO.
ES96918661T 1995-06-07 1996-06-03 Derivados de la dolastatina, su preparacion y su uso. Expired - Lifetime ES2188759T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides

Publications (1)

Publication Number Publication Date
ES2188759T3 true ES2188759T3 (es) 2003-07-01

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96918661T Expired - Lifetime ES2188759T3 (es) 1995-06-07 1996-06-03 Derivados de la dolastatina, su preparacion y su uso.
ES96918660T Expired - Lifetime ES2186783T3 (es) 1995-06-07 1996-06-03 Derivados de la dolastatina, su preparacion y uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96918660T Expired - Lifetime ES2186783T3 (es) 1995-06-07 1996-06-03 Derivados de la dolastatina, su preparacion y uso.

Country Status (33)

Country Link
US (1) US5831002A (es)
EP (2) EP0871656B1 (es)
JP (2) JP4221062B2 (es)
KR (2) KR100437986B1 (es)
CN (2) CN1182153C (es)
AR (2) AR003136A1 (es)
AT (2) ATE223431T1 (es)
AU (2) AU725170B2 (es)
BG (2) BG102125A (es)
BR (2) BR9609423A (es)
CA (2) CA2219818C (es)
CO (2) CO4700526A1 (es)
CZ (2) CZ293682B6 (es)
DE (2) DE69623472T2 (es)
DK (2) DK0832104T3 (es)
ES (2) ES2188759T3 (es)
HR (2) HRP960277A2 (es)
HU (2) HU228071B1 (es)
IL (2) IL122216A (es)
MX (2) MX9709146A (es)
MY (2) MY119042A (es)
NO (2) NO318384B1 (es)
NZ (2) NZ310443A (es)
PL (2) PL185762B1 (es)
PT (2) PT832104E (es)
RO (2) RO118953B1 (es)
SI (2) SI0871656T1 (es)
SK (1) SK282466B6 (es)
TR (2) TR199701545T1 (es)
TW (2) TW508357B (es)
UA (2) UA46776C2 (es)
WO (2) WO1996040752A1 (es)
ZA (2) ZA964711B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CN100350036C (zh) 2001-04-27 2007-11-21 宝洁公司 用于控制生物膜的装置和方法
WO2003051835A2 (en) * 2001-12-18 2003-06-26 Proteologics, Inc. Methods and compositions for the inhibition of viral release
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
CA2683098C (en) * 2007-04-12 2014-03-18 Scinopharm Taiwan Ltd. Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
KR102179369B1 (ko) * 2011-05-27 2020-11-16 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
AU662551B2 (en) * 1991-08-09 1995-09-07 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
EP0642530B1 (en) * 1992-05-20 1998-08-12 BASF Aktiengesellschaft Derivatives of dolastatin
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
MX9709147A (es) 1998-03-31
HUP9801910A2 (hu) 1999-01-28
CA2219818A1 (en) 1996-12-19
IL122216A (en) 2002-02-10
TR199701545T1 (xx) 1998-04-21
WO1996040751A1 (en) 1996-12-19
HUP9801817A3 (en) 1999-06-28
EP0832104A1 (en) 1998-04-01
CZ376397A3 (cs) 1998-06-17
CN1182153C (zh) 2004-12-29
PL323723A1 (en) 1998-04-14
SK282466B6 (sk) 2002-02-05
NZ310444A (en) 1999-11-29
CO4700527A1 (es) 1998-12-29
SK165397A3 (en) 1998-10-07
JP4221062B2 (ja) 2009-02-12
DE69623992T2 (de) 2003-05-22
KR100437986B1 (ko) 2004-09-18
PL185763B1 (pl) 2003-07-31
BG102125A (en) 1998-09-30
SI0832104T1 (en) 2003-08-31
CZ376597A3 (cs) 1998-06-17
MY119042A (en) 2005-03-31
PT832104E (pt) 2002-12-31
BR9609424A (pt) 2000-03-28
CA2219818C (en) 2008-05-20
RO119783B1 (ro) 2005-03-30
DE69623472T2 (de) 2003-08-21
JP3957751B2 (ja) 2007-08-15
HU228073B1 (hu) 2012-09-28
NO318384B1 (no) 2005-03-14
CZ293682B6 (cs) 2004-07-14
NZ310443A (en) 1999-10-28
ZA964710B (en) 1997-12-08
EP0832104B1 (en) 2002-09-04
CO4700526A1 (es) 1998-12-29
NO317670B1 (no) 2004-11-29
ES2186783T3 (es) 2003-05-16
CN1187198A (zh) 1998-07-08
DK0832104T3 (da) 2003-01-06
CA2219819C (en) 2008-05-20
NO975710D0 (no) 1997-12-05
WO1996040752A1 (en) 1996-12-19
UA46776C2 (uk) 2002-06-17
PT871656E (pt) 2002-12-31
DK0871656T3 (da) 2003-01-27
BG102152A (en) 1998-09-30
UA46775C2 (uk) 2002-06-17
ATE224910T1 (de) 2002-10-15
CN1182154C (zh) 2004-12-29
JPH11504653A (ja) 1999-04-27
NO975710L (no) 1998-02-02
CA2219819A1 (en) 1996-12-19
IL122215A (en) 2001-08-26
HUP9801817A2 (hu) 1998-11-30
AR003136A1 (es) 1998-07-08
KR100437985B1 (ko) 2004-09-18
NO975711L (no) 1998-01-30
TW424096B (en) 2001-03-01
AU6124196A (en) 1996-12-30
US5831002A (en) 1998-11-03
BR9609423A (pt) 1999-06-29
IL122215A0 (en) 1998-04-05
AU6124296A (en) 1996-12-30
ATE223431T1 (de) 2002-09-15
EP0871656A1 (en) 1998-10-21
AU725164B2 (en) 2000-10-05
SI0871656T1 (en) 2003-08-31
HRP960257A2 (en) 1998-02-28
MY124487A (en) 2006-06-30
HRP960277A2 (en) 1997-10-31
CN1187199A (zh) 1998-07-08
EP0871656B1 (en) 2002-09-25
PL185762B1 (pl) 2003-07-31
TW508357B (en) 2002-11-01
CZ293683B6 (cs) 2004-07-14
AU725170B2 (en) 2000-10-05
AR003427A1 (es) 1998-08-05
RO118953B1 (ro) 2004-01-30
HUP9801910A3 (en) 1999-06-28
PL323726A1 (en) 1998-04-14
JPH11504652A (ja) 1999-04-27
ZA964711B (en) 1997-12-08
HU228071B1 (hu) 2012-09-28
TR199701544T1 (xx) 1998-03-21
MX9709146A (es) 1998-03-31
IL122216A0 (en) 1998-04-05
KR19990022582A (ko) 1999-03-25
NO975711D0 (no) 1997-12-05
DE69623472D1 (de) 2002-10-10
KR19990022583A (ko) 1999-03-25
DE69623992D1 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
ES2188759T3 (es) Derivados de la dolastatina, su preparacion y su uso.
ES2175066T3 (es) Antagonistas triciclicos de la vasopresina.
ES2118955T3 (es) Derivados de dolastatina.
IT8821134A0 (it) Frazioni oligomeriche procianidoliche, loro procedimentodi preparazione e composizioni farmaceutiche che le contengono.
FI970522L (fi) Koostumukset ja menetelmät pidennetyn paikallisanestesian aikaansaamiseksi
MX9102353A (es) N,o-sulfados de heparosanos, su procedimiento de preparacion y las composiciones farmaceuticas que contienen.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
IT9022032A0 (it) L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
ITMI951367A0 (it) Derivati della colchicina loro uso e formulazioni che li contengono
MX9203505A (es) N-aril-n-(4-(1-alquilheterociclico)-piperidinil) amidas y composicines farmaceuticas y metodos que emplean dichos compuestos.
IT9021953A0 (it) Apparecchio didattico e di esercitazione di uso odontoiatrico.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2160308T3 (es) Nuevos derivados amino-metil-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
FI971462A0 (fi) Bentsisoksatsolijohdannaisia ja niitä sisältäviä torjuntaainekoostumuksia
MX9203616A (es) Derivados de 4-amidino cromano y de 4-amidino[3,2-c] piridina y composiciones farmaceuticas que los contienen.
ITMI912466A0 (it) Uso di 1,2 dipalmitoil-l-alfa-fosfatidil-n-n-dimetiletanolammina in composizione dermatologiche
ES2105633T3 (es) Derivados de pirimidinona condensada a heterociclos nitrogenados con actividad antagonista de a ii.
BR9106372A (pt) Derivados 1,5-benzotiazepinona,suas preparacoes e uso farmaceutico
DE69200210D1 (de) Klebrigkeitsprüfer.
ES2196802T3 (es) Lactatos de citronelilo y/o de dihidrocitronelilo, su preparacion y su utilizacion.
FI953081A0 (fi) Sekviterpeenit, niiden valmistaminen ja niiden käyttö inhibiittoreina, jotka vaikuttavat GABA-bentsodiatsepiinireseptoriin
BA96113A (bs) Derivati 12,11113-epoksi-tilozina i postupci za njihovo dobivanje
ITRM930002A0 (it) Antibiogramma e corredo diagnostico per la sua realizzazione.
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.